arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Prelude Therapeutics Inc

PRLD
$3.55 ▼ -0.55 (-13.41%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
31 Visible periods
24 Metrics
Peer-ranked Benchmarks
Price Chart
9
Health
Poor
Bearish
auto_awesome

Analytical Summary

Prelude Therapeutics Inc faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $349.3M
Dividend Yield —
Revenue Growth None
Op. Margin -270.9% ↗
ROIC -9.1% ↗
FCF / Share $-0.16 ↗
Trailing P/E —
Price / Book 2.6x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

31-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$5.70M
↑ +24.5% —
Net Income Profit after all expenses
$-10.38M
↑ +67.6% —
Operating Margin Operating profit as % of sales
-270.9%
↑ +12.5% —
FCF / Share Free cash flow per share
$-0.16
↑ +53.9% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability
0
Returns ↓
5
Cash Quality ↓
43

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 8 years · 31 quarters